Comment on 'Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study'

We would like to respond to the article 'Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single centre, cohort study.' (Br J Dermatol. 2013 Mar 29. doi: 10.1111/bjd.12341). (1) In this study adalimumab and adalimumab antibodies (ADA) measurement was done by using bridging ELISAs. The emphasis is put on the monitoring of drug concentrations rather than anti-drug antibodies as a useful tool in clinical practise. We agree with this emphasis though the blood samples for measurement of adalimumab concentrations and ADA were collected during the patients' routine clinic visits, without reference to the timing of the administration of their therapy (i.e. trough/non-trough not specified). This article is protected by copyright. All rights reserved